[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) filed a Form 144 notifying a proposed sale of 100 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,403, scheduled approximately for 09/29/2025. The filing reports total shares outstanding of 2,046,854, and shows the 100 shares were acquired as founders shares on 05/17/2022. The filer represents compliance with Rule 144 and states no undisclosed material adverse information. The filing also lists recent Rule 10b5-1 sales by Matthew Szot totaling 14,400 shares between 08/27/2025 and 09/25/2025 for gross proceeds of $179,166.01.

Positive

• Disclosed sale is small relative to total shares outstanding, suggesting limited market impact
• Prior sales executed under Rule 10b5-1, indicating prearranged trading plans and compliance intent
• Filer attests there is no undisclosed material adverse information

Negative

• Insider sales continue (14,400 shares in the past three months), which may prompt investor questions about insider selling activity

Insights

Securities Analyst

TL;DR: Small planned insider sale under Rule 144 and multiple 10b5-1 trades over recent months; not obviously material to valuation.

The Form 144 documents a proposed disposition of 100 common shares valued at $1,403 against a share base of 2,046,854, indicating the planned sale is immaterial in size (<0.01% of outstanding shares). The filing confirms the shares were acquired as founders shares in May 2022 and that the filer attests to no undisclosed material information. Recent 10b5-1 executions by an insider (14,400 shares, $179,166.01 proceeds) show ongoing programmed selling activity. For investors, these are routine compliance disclosures rather than company operational signals.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 and 10b5-1 practices; transparency is appropriate but continued insider sales warrant monitoring.

The notice adheres to required representations and identifies the brokerage and schedule for the proposed sale. The use of Rule 10b5-1 for prior transactions provides an affirmative defense against insider trading claims if plans were adopted properly. Although the amounts disclosed are small relative to total shares outstanding, recurring insider sales can prompt governance questions about insider confidence; however, the filing itself contains no evidence of undisclosed material developments.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100	1403.00	2046854	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			100	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/25/2025	10900	153182.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/24/2025	1500	20992.95
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Cadrenal Therapeutics (CVKD) report in this Form 144?

The filing notifies a proposed sale of 100 common shares via Morgan Stanley with an aggregate market value of $1,403, scheduled for 09/29/2025.

How many shares does Cadrenal Therapeutics have outstanding according to the filing?

The filing reports 2,046,854 shares outstanding.

When were the 100 shares being sold originally acquired?

The 100 shares were acquired as founders shares on 05/17/2022.

What recent insider sales are disclosed in the filing?

The filing lists Rule 10b5-1 sales by Matthew Szot totaling 14,400 shares on 08/27/2025, 08/28/2025, 09/24/2025, and 09/25/2025 for gross proceeds of $179,166.01.

Does the filer state there is any undisclosed material information?

The filer represents by signature that they do not know of any material adverse information that has not been publicly disclosed.